Incyte Corp. buy marge
Start price
17.11.16
/
50%
€95.52
Target price
18.09.17
€135.30
Performance (%)
12.51%
End price
18.09.17
€107.47
Summary
This prediction ended on 18.09.17 with a price of €107.47. The prediction had a final performance of 12.51%. marge has a follow-up prediction for Incyte Corp. where he still thinks Incyte Corp. is a Buy. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | 1.466% | 1.466% | 27.323% | 7.273% |
| iShares Core DAX® | -0.793% | 4.201% | 19.951% | 70.602% |
| iShares Nasdaq 100 | -2.376% | 0.857% | 4.704% | 103.322% |
| iShares Nikkei 225® | -2.701% | -0.147% | 12.609% | 44.593% |
| iShares S&P 500 | -1.689% | 1.244% | 3.144% | 64.741% |
Comments by marge for this prediction
In the thread Incyte Corp. diskutieren
marge stimmt der Buy-Einschätzung von datca zu: siehe Beschreibung
marge stimmt am 17.11.2016 der Buy-Einschätzung von datca mit dem Kursziel 120$ zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
(Laufzeit überschritten)